智通财经网·2026-03-16 09:39Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the transfer of the marketing authorization holder (MAH) for Ezetimibe tablets, indicating a strategic move to enhance its product portfolio and market presence [1]. Group 1: Company Actions - The company signed a contract with Beijing Sunshine Nuohua Pharmaceutical Research Co., Ltd. in May 2023 for the transfer of production technology and MAH rights for Ezetimibe tablets, which includes production, sales, and marketing rights [1]. - The transfer fee will be paid in stages by Xinhua Pharmaceutical to Sunshine Nuohua as per the contract [1]. - The transaction does not require approval from the company's board or shareholders, and it does not constitute a related party transaction or a major asset restructuring as per relevant regulations [1]. Group 2: Regulatory Approvals - Xinhua Pharmaceutical submitted a supplementary application for the change of the marketing authorization holder to the National Medical Products Administration in February 2026, which was accepted [1]. - The approval notification for the MAH transfer was received in March 2026, confirming that the application meets the requirements for post-marketing changes [1]. Group 3: Market Potential - Ezetimibe tablets are indicated for the treatment of primary hypercholesterolemia, homozygous familial hypercholesterolemia, and sitosterolemia [2]. - The projected sales revenue for Ezetimibe tablets in Chinese public medical institutions is approximately RMB 810 million in 2024 [2].